Imviva Biotech Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
107
- Latest Deal Type
-
Later Stage VC
- Investors
-
7
Imviva Biotech General Information
Description
Developer of allogeneic CAR-T cell therapies designed for cancers and autoimmune diseases. The company's technology applies immune-evasion science and an iterative design approach, providing allogeneic CAR-T cell therapies to overcome performance and persistence challenges.
Contact Information
Website
www.imvivabio.comCorporate Office
- Treehouse Building 16, Unit B1-2
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210046
- China
Corporate Office
- Treehouse Building 16, Unit B1-2
- Number 73 Tanmi Road, Jiangbei New District
- Nanjing, Jiangsu 210046
- China
Imviva Biotech Timeline
Imviva Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 01-Aug-2026 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 29-Nov-2024 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 06-Dec-2021 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 03-Jun-2021 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 24-Mar-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 22-Jul-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 14-Feb-2019 | $14.8M | $14.8M | Completed | Generating Revenue | |
| 1. Corporate | 01-Apr-2018 | Completed | Generating Revenue |
Imviva Biotech Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Imviva Biotech Patents
Imviva Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026040975-A1 | Antibody targeting cd33 and use thereof | Pending | 23-Aug-2024 | ||
| JP-2026505337-A | Enhanced cell therapy | Pending | 10-Feb-2023 | ||
| EP-4653524-A1 | Function-enhanced cell therapy | Pending | 10-Feb-2023 | ||
| EP-4653524-A4 | Function-enhanced cell therapy | Pending | 10-Feb-2023 | ||
| US-20260232731-A1 | Function-enhanced cell therapy | Pending | 10-Feb-2023 | A61K35/17 |
Imviva Biotech Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Imviva Biotech Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 7G Bioventures | Venture Capital | Minority | ||
| Qiming Venture Partners | Venture Capital | Minority | ||
| Hillhouse Investment Group | PE/Buyout | Minority | ||
| Lanchi Ventures | Venture Capital | Minority | ||
| Octagon Capital Advisors | Hedge Fund | Minority |
Imviva Biotech FAQs
-
When was Imviva Biotech founded?
Imviva Biotech was founded in 2017.
-
Where is Imviva Biotech headquartered?
Imviva Biotech is headquartered in Nanjing, China.
-
What is the size of Imviva Biotech?
Imviva Biotech has 107 total employees.
-
What industry is Imviva Biotech in?
Imviva Biotech’s primary industry is Drug Discovery.
-
Is Imviva Biotech a private or public company?
Imviva Biotech is a Private company.
-
What is Imviva Biotech’s current revenue?
The current revenue for Imviva Biotech is .
-
How much funding has Imviva Biotech raised over time?
Imviva Biotech has raised $125M.
-
Who are Imviva Biotech’s investors?
7G Bioventures, Qiming Venture Partners, Hillhouse Investment Group, Lanchi Ventures, and Octagon Capital Advisors are 5 of 7 investors who have invested in Imviva Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
